With 80% of its €50m impact fund deployed, Boehringer Ingelheim is backing startups tackling last-mile medicine delivery, e-pharmacy, and affordable outpatient care.
With 80% of its €50m impact fund deployed, Boehringer Ingelheim is backing startups tackling last-mile medicine delivery, e-pharmacy, and affordable outpatient care.
Funding has plunged to an eight-year low, shutdowns are mounting, and commercial VCs are nowhere to be seen. Inside the sector’s grant-dependency crisis.
